Cargando…
HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219970/ https://www.ncbi.nlm.nih.gov/pubmed/34178656 http://dx.doi.org/10.3389/fonc.2021.670673 |
_version_ | 1783711055891922944 |
---|---|
author | Yang, Ying Liu, Zhuogang Wang, Hongtao Zhang, Guojun |
author_facet | Yang, Ying Liu, Zhuogang Wang, Hongtao Zhang, Guojun |
author_sort | Yang, Ying |
collection | PubMed |
description | Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells. |
format | Online Article Text |
id | pubmed-8219970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82199702021-06-24 HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma Yang, Ying Liu, Zhuogang Wang, Hongtao Zhang, Guojun Front Oncol Oncology Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells. Frontiers Media S.A. 2021-06-09 /pmc/articles/PMC8219970/ /pubmed/34178656 http://dx.doi.org/10.3389/fonc.2021.670673 Text en Copyright © 2021 Yang, Liu, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Ying Liu, Zhuogang Wang, Hongtao Zhang, Guojun HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title | HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title_full | HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title_fullStr | HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title_full_unstemmed | HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title_short | HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma |
title_sort | hla-e binding peptide as a potential therapeutic candidate for high-risk multiple myeloma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219970/ https://www.ncbi.nlm.nih.gov/pubmed/34178656 http://dx.doi.org/10.3389/fonc.2021.670673 |
work_keys_str_mv | AT yangying hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma AT liuzhuogang hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma AT wanghongtao hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma AT zhangguojun hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma |